Home › Compound Library › Meloxicam (Mobic)

Meloxicam (Mobic)

Analgesicprescriptionoral · inferred

Preferential COX-2 inhibitor (enolic acid NSAID). Long half-life allows once-daily dosing. At therapeutic doses, more COX-2 selective than traditional NSAIDs, offering some GI protection — though less selective than celecoxib. One of the most prescribed NSAIDs globally for osteoarthritis and rheumatoid arthritis. Hepatically metabolized by CYP2C9; renal excretion of metabolites. 89% oral bioavailability.

Projected serum levels — 7.5 mg, once daily

Meloxicam (Mobic)
Meloxicam (Mobic) modeled serum levels, 7.5 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 3 days. 0 5 10 15 20 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 3
Meloxicam (Mobic) modeled serum levels with a loading dose of 13.5 mg, then 7.5 mg once daily The first dose is larger so levels approach steady state faster. 0 5 10 15 20 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 7.5 mg once daily (oral).

Loading schedule: 13.5 mg on day 1, then 7.5 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~3 days: peak ≈ 10.1 mg, trough ≈ 5.3 mg body load. Population-based estimate over 15 days for a 7.5 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Analgesic
Route modeled
Oral
Model confidence
inferred
Half-life
20 h
Common dose
7.5 mg
Suggested maximum
15 mg/day
Reference dose range
3.8–15 mg (single dose)
Suggested cadence
once daily
Validated against
15 mg oral — Cmax 2 mg/L at 5 h

Documented interactions

  • danger
    Carbamazepine (Tegretol) + Meloxicam (Mobic) CYP induction

    Carbamazepine (Tegretol) inducer of CYP2C9 predicted to change Meloxicam (Mobic) AUC by ~0.46x

  • danger
    CBD (Cannabidiol) + Meloxicam (Mobic) CYP inhibition

    CBD (Cannabidiol) reversible_inhibitor of CYP2C9 predicted to change Meloxicam (Mobic) AUC by ~2.20x

  • danger
    Efavirenz (Sustiva) + Meloxicam (Mobic) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Meloxicam (Mobic) AUC by ~0.39x

  • danger
    Fluconazole + Meloxicam (Mobic) CYP inhibition

    Fluconazole reversible_inhibitor of CYP2C9 predicted to change Meloxicam (Mobic) AUC by ~2.20x

  • danger
    Fluvoxamine (Luvox) + Meloxicam (Mobic) CYP inhibition

    Fluvoxamine (Luvox) reversible_inhibitor of CYP2C9 predicted to change Meloxicam (Mobic) AUC by ~2.20x

  • danger
    Levothyroxine (Synthroid) + Meloxicam (Mobic) Protein binding

    Meloxicam (Mobic) may displace Levothyroxine (Synthroid) from plasma protein binding sites, transiently raising free drug concentration. This drug has a narrow therapeutic index; free concentration…

Serum checks 220 modeled interaction pairings for meloxicam (mobic) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Meloxicam: a review of its pharmacology and clinical efficacy in osteoarthritis Fleischmann R et al. · Clinical Therapeutics, 2002 DOI

    Large review of clinical trials confirming meloxicam 7.5-15 mg/day is as effective as diclofenac and piroxicam for osteoarthritis pain with 40-50% fewer GI adverse events.

  2. Clinical pharmacokinetics of meloxicam: a review Turck D et al. · European Journal of Drug Metabolism and Pharmacokinetics, 1996 DOI

    PK review establishing meloxicam half-life of 20 hours, 89% bioavailability, 99.4% protein binding, CYP2C9 metabolism, and steady-state achievement in 3-5 days with once-daily dosing.

2 published studies referenced in the app, each with a plain-language summary.